CN109200063A - Bacteroides fragilis is in preparation for treating and preventing the application in tuberculosis - Google Patents
Bacteroides fragilis is in preparation for treating and preventing the application in tuberculosis Download PDFInfo
- Publication number
- CN109200063A CN109200063A CN201710516131.9A CN201710516131A CN109200063A CN 109200063 A CN109200063 A CN 109200063A CN 201710516131 A CN201710516131 A CN 201710516131A CN 109200063 A CN109200063 A CN 109200063A
- Authority
- CN
- China
- Prior art keywords
- bacteroides fragilis
- tuberculosis
- inactivation
- treating
- lysate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000606124 Bacteroides fragilis Species 0.000 title claims abstract description 127
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 235000013373 food additive Nutrition 0.000 claims abstract description 10
- 239000002778 food additive Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims description 35
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 27
- 239000012228 culture supernatant Substances 0.000 claims description 21
- 239000006166 lysate Substances 0.000 claims description 21
- 230000002779 inactivation Effects 0.000 claims description 19
- 230000004048 modification Effects 0.000 claims description 18
- 238000012986 modification Methods 0.000 claims description 18
- 230000006798 recombination Effects 0.000 claims description 18
- 230000009466 transformation Effects 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 241000606125 Bacteroides Species 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000568 immunological adjuvant Substances 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 235000012241 calcium silicate Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 235000012222 talc Nutrition 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 241000682973 Quasibacillus Species 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 238000005238 degreasing Methods 0.000 claims 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 abstract description 15
- 230000001681 protective effect Effects 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000002365 anti-tubercular Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 2
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000254223 Syntexis Species 0.000 description 1
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960002109 tuberculosis vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention belongs to biomedicine field, in particular to bacteroides fragilis prevents and/or treats the application in tuberculosis for assisting in preparation.The present invention also provides bacteroides fragilis in preparation for treating and/or preventing the application in tuberculosis composition, food, health care product and food additives.Bacteroides fragilis provided by the present invention can effectively be treated and/or prevent tuberculosis, and enhance the immune protective effect of tuberculosis BCG vaccine BCG, have broad application prospects.
Description
Technical field
The present invention relates to biomedicine fields, and in particular to bacteroides fragilis is in preparation for preventing and/or treating tuberculosis
Application in the drug of disease.
Background technique
Tuberculosis caused by being infected because of mycobacterium tuberculosis (Mycobacterium tuberculosis, M.tb)
(Tuberculosis, TB) is one of the deadly infectious disease with highest infection rate, pathogenicity rate and lethality, is the whole world and China
One of public health security threat the severeest faced.The newest whole world knot in 2016 of the World Health Organization (WHO) publication
Core epidemic situation annual report is shown: tuberculosis new cases in 2016 are more than 9,000,000 people, and lethal number lungy reaches 2,000,000 people,
Already exceed dead person's number caused by HIV/AIDS infects；Moreover, the tuberculosis epidemic situation and mycobacterium tuberculosis infection conditions all phases in China
It is one of 22 tuberculosis high burden countries in the whole world, tuberculosis patient numerical digit is at the forefront in the world when serious.
The mankind are after infecting mycobacterium tuberculosis, it is easy to develop into active tuberculosis, generate night sweat, persistent cough,
The clinical symptoms such as syntexis, serious person even develop into multi-drug resistant tuberculosis (MDR-TB) or super drug resistance tuberculosis (XDR-
TB), the body health and labour capacity of sufferer are seriously damaged.
Mycobacterium tuberculosis can invade susceptible body by respiratory tract, alimentary canal or skin injury, cause Various Tissues device
The tuberculosis of official, wherein to cause pulmonary tuberculosis to be most by respiratory tract.Because there is a large amount of normal floras to live away from home in enteron aisle, tuberculosis point
Branch bacillus must could be survived by competition and be adhered to permissive cell.So mycobacterium tuberculosis is more difficult to be caused to send out in enteron aisle
Disease.But without normal flora in alveolar, mycobacterium tuberculosis can be by the sucking of droplet droplet or germ-laden Dust, therefore pulmonary tuberculosis
It is more common, along with lung's oxygen and blood flow, nutrition are abundant, it is very suitable to the growth of mycobacterium tuberculosis, so lung is very
It is easy infection tuberculosis.
Traditional pulmonary tuberculosis control method includes early diagnosis and correct processing consumptive, tracking contactee and inoculation
BCG.Injection tuberculosis vaccine BCG vaccine (BCG) is the phthisical most important method of prevention.BCG vaccine (BCG) is to use at present
Widest vaccine；But BCG vaccine is bad in many local using effects in the world, is especially easy to lose protection to adult.To not
Protection efficiency with crowd is inconsistent, and generally 0~85%, but also primary infection cannot be prevented, it is often more important that it cannot
Prevent the re-ignition of lung's latent infection, and the latter is exactly the main source that mycobacterium tuberculosis is propagated in crowd.Therefore, BCG
It is inoculated with and the effect for controlling mycobacterium tuberculosis transmission of infection is limited.
In addition, so that treatment lungy is played and is achieved certain progress although antituberculotic is come out one after another, by
In Case management still ten sectional specification of tuberculosis patient, irregular chemotherapy abuses antituberculotic, makes drug resistance of tuberculosis situation
It gets worse, and the variation of drug resistance tends to a variety of drugs drug resistance simultaneously, this is caused greatly to preventing and controlling lungy
It is difficult.Therefore new tuberculotherapy method is found, the antituberculotic of especially anti-multidrug resistance is to protection people's body
Health is of great significance.
Probiotics is a kind of active microorganism beneficial to host, is to be colonized in human body intestinal canal, in reproductive system, can generate
Definite health efficacy has so as to improve the active beneficial microorganism general name of host's microecological balance, performance beneficial effect
Alleviate the multiple efficacies such as lactose intolerance, adjustment intestinal microecology, enhancing autoimmunity, current more and more researchers
Probiotics is focused on, gradually recognizes their huge therapeutic efficiency.
After probiotics is in intake humans and animals body, they can be settled down on intestinal mucosa, in the built-in group of enteron aisle and be prevented
Only harmful microorganism adheres on it, can by keep enteral natural microorganisms fauna, promote bion be formed health can
The microorganism formulation of growth helps the health for maintaining humans and animals.Therefore effectively inhibit tuberculosis using probiotics or beneficial flora
Mycobacteria effectively assists preventive and therapeutic action in the infection and breeding of lung so as to play.
Bacteroides fragilis (Bacteroides fragilis) be a kind of Gram-negative, rod-shaped, both ends blunt circle and
Dense dye has pod membrane, without brood cell, motorless obligate anaerobes, is divided into and produces enterotoxin type and non-production enterotoxin type.Fragility is quasi-
Bacillus is mainly stored in colon as people and a part of animal intestinal tract normal flora, in addition, respiratory tract gastrointestinal tract and uropoiesis are raw
Growth can also be colonized by growing.It is numerous studies have shown that bacteroides fragilis to prevention and treatment acute chronic enteritis, flora imbalance, upper respiratory tract sense
Dye and neurosis etc. have good therapeutic effect.
But bacteroides fragilis auxiliary there is no to prevent and treat phthisical report and patent application at present.
Summary of the invention
It can be effectively pre- the technical problem to be solved by the present invention is to aiming at the above technical problems to be solved, provide one kind
Prevent and/or treat measure lungy, especially bacteroides fragilis to prepare the application in antituberculosis infection medicine, including crisp
Application of the weak bacteroid in the antibacterials that preparation is used for mycobacterium tuberculosis, and the drug including bacteroides fragilis, epidemic disease
Seedling composition, food, health care product, food additives, immunologic adjuvant etc..
To achieve the goals above, the present invention provides bacteroides fragilis (Bacteroides fragilis) uses in preparation
Application in the antibacterials of the mycobacterium tuberculosis for the treatment of and/or prevention.
According to an aspect of the present invention, in above-mentioned application, the bacteroides fragilis is any one in following: crisp
Weak bacteroid viable bacteria body；Fragility through genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation intends bar
Bacterium；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
Preferably, in application according to the present invention, tuberculosis pathogen is mycobacterium tuberculosis H37RV standard strain.
In order to which above-mentioned purpose is better achieved, the present invention also provides one kind for treating and/or preventing medicine lungy
Compositions, wherein described pharmaceutical composition includes the bacteroides fragilis of pharmacy effective dose and its pharmaceutically acceptable
Carrier.Wherein, the bacteroides fragilis is active constituent.
According to an aspect of the present invention, in above-mentioned pharmaceutical composition, the bacteroides fragilis is any in following
It is a kind of: bacteroides fragilis viable bacteria body；Through the crisp of genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation
Weak bacteroid；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
Preferably, in above-mentioned pharmaceutical composition, described pharmaceutical composition can be pharmaceutically feasible any or more
Kind of dosage form is including but not limited to tablet, capsule, oral solution or freeze dried powder.
Preferably, in above-mentioned pharmaceutical composition, the pharmaceutically acceptable carrier be defatted milk, lactose, glucose,
Sucrose, D-sorbite, mannose, trehalose, starch, Arabic gum, calcium phosphate, alginates, gelatin, calcium silicates, fine crystallization are fine
Tie up element, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol,
One of talcum, magnesium stearate or mineral oil or a variety of mixtures.
In order to which above-mentioned purpose is better achieved, the present invention also provides one kind for treating and/or preventing food lungy
Product, wherein the food includes any one in following: bacteroides fragilis viable bacteria body；Through genetic recombination, transformation or modification,
Attenuation is chemically treated, the bacteroides fragilis of physical treatment or inactivation；Bacteroides fragilis lysate；And/or bacteroides fragilis culture
Supernatant.
According to an aspect of the present invention, in above-mentioned application, the bacteroides fragilis is any one in following: crisp
Weak bacteroid viable bacteria body；Fragility through genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation intends bar
Bacterium；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
In order to which above-mentioned purpose is better achieved, the present invention also provides one kind for treating and/or preventing food lungy
Product additive, wherein the food additives include any one in following: bacteroides fragilis viable bacteria body；Through genetic recombination,
Transformation or modification attenuation, are chemically treated, the bacteroides fragilis of physical treatment or inactivation；Bacteroides fragilis lysate；And/or it is crisp
Weak bacteroid culture supernatant.
According to an aspect of the present invention, in above-mentioned food additives, the bacteroides fragilis is any in following
It is a kind of: bacteroides fragilis viable bacteria body；Through the crisp of genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation
Weak bacteroid；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
In order to which above-mentioned purpose is better achieved, the present invention also provides one kind for treating and/or preventing guarantor lungy
Strong product, wherein the health care product includes any one in following: bacteroides fragilis viable bacteria body；Through genetic recombination, it is transformed or repairs
Decorations attenuation, are chemically treated, the bacteroides fragilis of physical treatment or inactivation；Bacteroides fragilis lysate；And/or bacteroides fragilis
Culture supernatant.
According to an aspect of the present invention, in above-mentioned health care product, the bacteroides fragilis is any one in following:
Bacteroides fragilis viable bacteria body；Fragility through genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation intends bar
Bacterium；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
In order to which above-mentioned purpose is better achieved, it is immune for enhancing tuberculosis BCG vaccine BCG that the present invention also provides one kind
The adjuvant of effect, wherein the immunologic adjuvant includes any one in following: bacteroides fragilis viable bacteria body；Through genetic recombination,
Transformation or modification attenuation, are chemically treated, the bacteroides fragilis of physical treatment or inactivation；Bacteroides fragilis lysate；And/or it is crisp
Weak bacteroid culture supernatant.
According to an aspect of the present invention, in above-mentioned immunologic adjuvant, the bacteroides fragilis is any one in following
Kind: bacteroides fragilis viable bacteria body；Fragility through genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation
Bacteroid；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
The present invention is by carrying out detection and identification, this hair to the effect of bacteroides fragilis in a variety of tuberculosis infection models
Bright to be experimentally confirmed, bacteroides fragilis has stronger inhibitory effect to mycobacterium tuberculosis duplication and can significantly increase card
The prevention of Jie's seedling BCG or treatment immune protective effect lungy.
Detailed description of the invention
Fig. 1 is to detect bacteroides fragilis and inactivate bacteroides fragilis to flow the therapeutic effect experiment that mycobacterium tuberculosis infects
Journey schematic diagram.
Fig. 2 is to detect bacteroides fragilis and inactivate bacteroides fragilis to flow the prevention effect experiment that mycobacterium tuberculosis infects
Journey schematic diagram.
Fig. 3 is mycobacterium tuberculosis (M.tb) carrying capacity situation comparison diagram in mouse lung after bacteroides fragilis treatment.
Fig. 4 is mycobacterium tuberculosis (M.tb) carrying capacity situation pair in mouse lung after bacteroides fragilis enhancing BCG immunoprotection
Than figure.
Specific embodiment
Below in conjunction with specific embodiment, the invention will be further described.It should be pointed out that by the use in the present invention
In treating and/or prevent bacteroides fragilis lungy or the pharmaceutical composition containing bacteroides fragilis of the invention, food, guarantor
Strong product and food additives can be applied to indication described above and show described above after being applied to subject
Function, all dosage forms within the scope of the present invention have tested, and hereinafter, only to illustrate, only describe in embodiment
A wherein small part, however should not be construed as limitation of the present invention.
Signified bacteroides fragilis of the invention includes but is not limited to bacteroides fragilis viable bacteria body, inactivates bacteroides fragilis, is crisp
Any one in weak bacteroid lysate and/or bacteroides fragilis culture supernatant.The tuberculosis pathogen is tuberculosis point
Branch bacillus H37RV standard strain.
The present invention also provides a kind of pharmaceutical composition for antituberculosis, described pharmaceutical composition includes that pharmacy is effective
The bacteroides fragilis of dosage.Wherein, so-called " pharmacy effective dose " is 106-1010CFU, preferably 109CFU.The fragility
Bacteroid includes any one in following: bacteroides fragilis viable bacteria body；At genetic recombination, transformation or modification, attenuation, chemistry
It manages, the bacteroides fragilis of physical treatment or inactivation；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.It is described
Pharmaceutical composition is tablet, capsule, oral solution or freeze dried powder.The pharmaceutically acceptable carrier includes but is not limited to be
It is defatted milk, lactose, glucose, sucrose, D-sorbite, mannose, trehalose, starch, Arabic gum, calcium phosphate, alginates, bright
Glue, calcium silicates, fine crystallization cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, hydroxybenzoic acid first
One of ester, nipasol, talcum, magnesium stearate or mineral oil are a variety of.
Bacteroides fragilis of the invention can also be made into food, health care product or food additives etc..The food, health care
Product or food additives contain any one in following: bacteroides fragilis viable bacteria body；Through genetic recombination, transformation or modification,
Attenuation is chemically treated, the bacteroides fragilis of physical treatment or inactivation；Bacteroides fragilis lysate；And/or bacteroides fragilis culture
Supernatant.These food, health care product or food additives are used equally for treating and/or preventing tuberculosis.
Embodiment 1: bacteroides fragilis culture
Cultural method
Step 1: taking a freeze-drying to save bacteroides fragilis (Bacteroides fragilis) strain, 200 μ L are added
TSB culture medium redissolves, and draws 20 bases, blood plate scribing line, after the pumping of anaerobic jar gas control system 37 in biochemical cultivation case
Ware, Anaerobic culturel 48h；
Step 2: picking monoclonal colonies access 10mL TSB culture medium, 37, Anaerobic culturel 12h；
Step 3: take 1 bottle of 500mL TSB culture medium, access 1% (v/v) strain, 37, Anaerobic culturel 48h；
Step 4: taking bacterium solution to be centrifuged, 6000rpm, 10min.With brine 2 times, bacterium finally is redissolved with physiological saline
Mud is spare and carries out count plate.
Embodiment 2: the mouse experiment that bacteroides fragilis acts on mycobacterium tuberculosis treatment of infection
Fig. 1 is to detect bacteroides fragilis and inactivate bacteroides fragilis to flow the therapeutic effect experiment that mycobacterium tuberculosis infects
Journey schematic diagram.
Fig. 2 is to detect bacteroides fragilis and inactivate bacteroides fragilis to flow the prevention effect experiment that mycobacterium tuberculosis infects
Journey schematic diagram.
1, cultural method
Bacteroides fragilis cultural method is the same as embodiment 1.
2, preparation of samples
1) preparation of bacteroides fragilis ZY-312 viable bacteria body
Step 1: taking a freeze-drying to save strain, 200 freeze-dryings are added and save bacterium culture medium, redissolve, draw 20 bases, blood is flat
Ware scribing line, anaerobic jar gas control system pumping after in biochemical cultivation case 37 wares, Anaerobic culturel 48h；
Step 2: picking monoclonal colonies access 10mL TSB culture medium, 37 bases, Anaerobic culturel 12h；
Step 3: take 1 bottle of 500mL TSB culture medium, access 1% (v/v) strain, 37, Anaerobic culturel 48h；
Step 4: take bacterium solution to be centrifuged, it is centrifuged with centrifuge, centrifugal condition 6000rpm, 10min.
With brine 2 times, it is spare and carry out count plate that bacterium mud finally is redissolved with physiological saline.
2) bacteroides fragilis inactivates thallus
30min is heated in 70 degree of water-baths of temperature obtains inactivated bacterial liquid.
3) bacteroides fragilis lysate
Bacteroides fragilis cultivates bacterium solution, carries out sonioation method processing using Ultrasonic Cell Disruptor, breaks 2 seconds, stop 5 seconds, continues
20 minutes, obtain bacteroides fragilis lysate.
4) bacteroides fragilis culture supernatant
Bacteroides fragilis cultivates bacterium solution, is centrifuged with centrifuge, centrifugal condition 6000rpm, 10min, 40, centrifuging and taking
Supernatant obtains bacteroides fragilis culture supernatant.
3, the mouse experiment that bacteroides fragilis acts on mycobacterium tuberculosis treatment of infection
Experimental animal: C57BL/6 mouse 3~4 weeks 18, the state of mind is good, is purchased from Zhongshan University's Experimental Animal Center.
Mouse is randomly divided into 3 groups, every group 6,3 groups are respectively control group, viable bacteria stomach-filling group, inactivated bacteria stomach-filling group
Experimentation and result:
With mycobacterium tuberculosis H37RV standard strain infecting mouse, then stomach-filling 10 was distinguished to 3 groups of mouse in every 3 days9CFU
Bacteroides fragilis, inactivation bacteroides fragilis and control, mouse continuous gavage 1 week, measure weight daily.
Referring to Fig. 3, Fig. 3 is the results show that tubercle bacillus carrying capacity highest, lung pathologies disease in control group mice lung during test
Shape aggravates, and stomach-filling bacteroides fragilis each group, mycobacterium tuberculosis carrying capacity is remarkably decreased, and has significant difference with control group.Table
Bright bacteroides fragilis can inhibit mycobacterium tuberculosis to replicate, and control pathology disease damage lungy, improve tuberculosis symptoms.
Embodiment 3: the pulmonary tuberculosis BCG vaccine BCG protection effect based on bacteroides fragilis adjuvant
Caused tuberculosis infection is infected for mycobacterium tuberculosis in order to assess the adjuvant based on bacteroides fragilis and provide
The ability of protection carries out C57BL/6 mouse using in viable bacteria bacteroides fragilis and inactivated bacteria bacteroides fragilis and control PBS
BCG immunity inoculation.
After last time vaccine inoculation 2 weeks, malicious mouse is attacked by the mycobacterium tuberculosis of intraperitoneal injection approach work.
The ability that vaccine reduces mycobacterium tuberculosis carrying capacity is measured after 4 weeks in lung.These data show that using bacteroides fragilis and
Significant level of protection (Fig. 4) of its inactivated bacteria as adjuvant.
From the above results, it can be seen that bacteroides fragilis of the invention is led for preventing and/or treating mycobacterium tuberculosis infection
The tuberculosis of cause has good effect, and safe and non-toxic, provides new selection to treat and/or preventing tuberculosis, has
Wide application prospect.
Certainly, the present invention can also have other various embodiments, without deviating from the spirit and substance of the present invention, ripe
It knows those skilled in the art and makes various corresponding changes and modifications, but these corresponding changes and change in accordance with the present invention
Shape all should fall within the scope of protection of the appended claims of the present invention.
Claims (10)
1. bacteroides fragilis preparation for treat and prevent mycobacterium tuberculosis (Mycobacterium tuberculosis,
M.tb the application in tuberculosis caused by) infecting.
2. application according to claim 1, which is characterized in that the bacteroides fragilis is any one in following: fragility is quasi-
Bacillus viable bacteria body；Bacteroides fragilis through genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation；It is crisp
Weak bacteroid lysate；And/or bacteroides fragilis culture supernatant.
3. one kind is for treating and preventing tuberculosis composition, which is characterized in that described pharmaceutical composition includes pharmacy
The bacteroides fragilis of effective dose and its pharmaceutically acceptable carrier.
4. pharmaceutical composition according to claim 3, which is characterized in that the bacteroides fragilis is any one in following:
Bacteroides fragilis viable bacteria body；Fragility through genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation intends bar
Bacterium；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
5. pharmaceutical composition according to claim 3, which is characterized in that described pharmaceutical composition is tablet, capsule, mouth
Take liquid or freeze dried powder.
6. pharmaceutical composition according to claim 3, which is characterized in that the pharmaceutically acceptable carrier is degreasing
Milk, lactose, glucose, sucrose, D-sorbite, mannose, trehalose, starch, Arabic gum, calcium phosphate, alginates, gelatin,
Calcium silicates, fine crystallization cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate,
One of nipasol, talcum, magnesium stearate or mineral oil or a variety of mixtures.
7. one kind is for treating and preventing food lungy, which is characterized in that the food includes any one in following:
Bacteroides fragilis viable bacteria body；Fragility through genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation intends bar
Bacterium；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
8. one kind is for treating and preventing health care product lungy, which is characterized in that the health care product includes any in following
It is a kind of: bacteroides fragilis viable bacteria body；Through the crisp of genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation
Weak bacteroid；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
9. one kind is for treating and preventing food additives lungy, which is characterized in that the food additives include following
In any one: bacteroides fragilis viable bacteria body；Through genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or
The bacteroides fragilis of inactivation；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
10. one kind is for treating and preventing immunologic adjuvant lungy, which is characterized in that the immunologic adjuvant includes in following
Any one: bacteroides fragilis viable bacteria body；Through genetic recombination, transformation or modification, attenuation, chemical treatment, physical treatment or inactivation
Bacteroides fragilis；Bacteroides fragilis lysate；And/or bacteroides fragilis culture supernatant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710516131.9A CN109200063A (en) | 2017-06-29 | 2017-06-29 | Bacteroides fragilis is in preparation for treating and preventing the application in tuberculosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710516131.9A CN109200063A (en) | 2017-06-29 | 2017-06-29 | Bacteroides fragilis is in preparation for treating and preventing the application in tuberculosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109200063A true CN109200063A (en) | 2019-01-15 |
Family
ID=64976725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710516131.9A Pending CN109200063A (en) | 2017-06-29 | 2017-06-29 | Bacteroides fragilis is in preparation for treating and preventing the application in tuberculosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109200063A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112587552A (en) * | 2020-09-17 | 2021-04-02 | 大连图腾生命科学发展有限公司 | Application of bacteroides fragilis839 in preparation of medicine and food for treating or assisting in treating immune-related diseases |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060234219A1 (en) * | 2001-05-31 | 2006-10-19 | Tsuneya Ohno | Method for detecting and identifying microorganism causative of infection |
| CN103142656A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating colon cancer |
| CN104363904A (en) * | 2012-04-20 | 2015-02-18 | 亨内平生命科学公司 | Compositions for topical treatment of microbial infections |
| CN105358141A (en) * | 2013-05-01 | 2016-02-24 | 尼奥酷里私人有限公司 | Methods for treating bacterial infections |
| CN105434476A (en) * | 2015-10-29 | 2016-03-30 | 广州知易生物科技有限公司 | Application of bacteroides fragilis to prevention and/or treatment of inflammatory bowel diseases (IBDs) |
| WO2016153952A1 (en) * | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Methods of treating bacterial infections and fungal infections using enantiopure deuterium-enriched pioglitazone |
| CN106399141A (en) * | 2015-07-31 | 2017-02-15 | 广州知易生物科技有限公司 | Bacteroides fragilis and applications thereof |
| CN107034279A (en) * | 2017-05-05 | 2017-08-11 | 中山大学 | Application of the tuberculosis microbial markers in the reagent of diagnosis of tuberculosis is prepared |
| CN109528775A (en) * | 2017-09-22 | 2019-03-29 | 中山大学 | Bacteroides fragilis is preparing the application in the drug for treating and preventing tumour |
| CN109793761A (en) * | 2017-11-17 | 2019-05-24 | 中山大学 | It is a kind of for enhancing the composition and preparation method thereof of T cell immune function |
| CN109908184A (en) * | 2017-12-12 | 2019-06-21 | 中山大学 | Bacteroides fragilis is in preparation for inducing the application in gamma delta T cells proliferation and/or the drug accumulated |
-
2017
- 2017-06-29 CN CN201710516131.9A patent/CN109200063A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060234219A1 (en) * | 2001-05-31 | 2006-10-19 | Tsuneya Ohno | Method for detecting and identifying microorganism causative of infection |
| CN104363904A (en) * | 2012-04-20 | 2015-02-18 | 亨内平生命科学公司 | Compositions for topical treatment of microbial infections |
| CN103142656A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating colon cancer |
| CN105358141A (en) * | 2013-05-01 | 2016-02-24 | 尼奥酷里私人有限公司 | Methods for treating bacterial infections |
| WO2016153952A1 (en) * | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Methods of treating bacterial infections and fungal infections using enantiopure deuterium-enriched pioglitazone |
| CN106399141A (en) * | 2015-07-31 | 2017-02-15 | 广州知易生物科技有限公司 | Bacteroides fragilis and applications thereof |
| CN105434476A (en) * | 2015-10-29 | 2016-03-30 | 广州知易生物科技有限公司 | Application of bacteroides fragilis to prevention and/or treatment of inflammatory bowel diseases (IBDs) |
| CN107034279A (en) * | 2017-05-05 | 2017-08-11 | 中山大学 | Application of the tuberculosis microbial markers in the reagent of diagnosis of tuberculosis is prepared |
| CN109528775A (en) * | 2017-09-22 | 2019-03-29 | 中山大学 | Bacteroides fragilis is preparing the application in the drug for treating and preventing tumour |
| CN109793761A (en) * | 2017-11-17 | 2019-05-24 | 中山大学 | It is a kind of for enhancing the composition and preparation method thereof of T cell immune function |
| CN109908184A (en) * | 2017-12-12 | 2019-06-21 | 中山大学 | Bacteroides fragilis is in preparation for inducing the application in gamma delta T cells proliferation and/or the drug accumulated |
Non-Patent Citations (5)
| Title |
|---|
| KATHRYN WINGLEE等: "Aerosol Mycobacterium tuberculosis infection causes rapid loss of diversity in gut microbiota", 《PLOS ONE》 * |
| M P EL"SHANSKAIA等: "Effects of non-clostridial anaerobic infection on the course of chronic pulmonary tuberculosis in experimental animals", 《PROBLEMY TUBERKULEZA》 * |
| NARGIS KHAN等: "Alteration in the Gut Microbiota Provokes Susceptibility to Tuberculosis", 《FRONTIERS IN IMMUNOLOGY》 * |
| 冯淑贞等: "脆弱拟杆菌的研究进展", 《微生物学通报》 * |
| 李百远等: "肠道菌群与结核杆菌感染相关的研究进展", 《临床医学进展》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112587552A (en) * | 2020-09-17 | 2021-04-02 | 大连图腾生命科学发展有限公司 | Application of bacteroides fragilis839 in preparation of medicine and food for treating or assisting in treating immune-related diseases |
| CN112587552B (en) * | 2020-09-17 | 2023-09-12 | 大连图腾生命科学发展有限公司 | Application of bacteroides fragilis839 in preparing medicament for treating or assisting in treating immune related diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4892296B2 (en) | Vaccines for fish edovagerosis and streptococcal disease | |
| WO2017020784A1 (en) | Bacteroides fragilis and application thereof | |
| JP6263277B2 (en) | Novel bacteriophage and compositions containing the same | |
| CN109806389B (en) | Haemophilus parasuis trivalent inactivated vaccine and application thereof | |
| CN106822890A (en) | A kind of pharmaceutical composition for preventing and treating diarrhea of weaned piglets and its preparation method and application | |
| CN105746606A (en) | Clinical laboratory indoor disinfector and preparation method thereof | |
| CN114107134B (en) | Brevibacillus laterosporus and application thereof | |
| CN108066758B (en) | Raccoon dog canine distemper-parvovirus enteritis bigeminal live vaccine and preparation method and application thereof | |
| CN107164273B (en) | A kind of strong 2 type Streptococcus suis of serum of immunogenicity and its application | |
| CN108103029A (en) | The bacteriophage of one plant of cleavable ox source Streptococcusagalactiae and its application | |
| CN109200063A (en) | Bacteroides fragilis is in preparation for treating and preventing the application in tuberculosis | |
| CN116121154B (en) | Leuconostoc lactis and application thereof | |
| CN107823326A (en) | A kind of fish pathogens bacteria inhibitor | |
| CN109609418B (en) | Erysipelothrix rhusiopathiae and application thereof | |
| CN106389475B (en) | Bacteroides fragilis is preventing and/or is treating the application in meningitis | |
| CN106267193A (en) | A kind of for infusion of medicine agent treating bovine mastitis and its preparation method and application | |
| CN105274032A (en) | Lactobacillus reuteri antagonizing Campylobacter jejuni and inhibiting flaA gene expression of Campylobacter jejuni | |
| CN101829321A (en) | Vaccine for preventing red head disease of Pseudobagrus fulvidraco | |
| CN105238727B (en) | A kind of antagonism campylobacter jejuni and the lactobacillus plantarum for inhibiting its flaA gene expression | |
| CN113101318A (en) | A Coptidis rhizoma extractive solution and its application in treating animals infected with Staphylococcus pseudointermedius | |
| CN111467469A (en) | New clinical application of bupleurum tenue particles and antibiotics | |
| López-Martín et al. | Prospective observational cohort study of the efficacy of bacterial immune prophylaxis in the prevention of uncomplicated, recurrent urinary tract infections | |
| CN103961378A (en) | Chinese herbal medicine micro-ecological preparation for subsidiarily preventing and treating pulmonary tuberculosis | |
| CN102114241B (en) | Attenuated live vaccine and application thereof | |
| CN102973633A (en) | Method for screening anti-bacterial adhesion inhibitors and preparation of anti-adhesion oral liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zeng Gucheng Inventor before: Zeng Gucheng |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190910 Address after: 518054 Donghua Garden, Nanshan Street, Nanshan District, Shenzhen City, Guangdong Province, 810 Applicant after: SHENZHEN YUEYAO LIFE TECHNOLOGY Co.,Ltd. Address before: 510275 Xingang West Road, Guangdong, China, No. 135, No. Applicant before: Sun Yat-sen University |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200724 Address after: 3009 venture capital building, No.9 Tengfei Road, huanggekeng community, Longcheng street, Longgang District, Shenzhen City, Guangdong Province Applicant after: Ruiwei (Shenzhen) Biotechnology Co.,Ltd. Address before: 518054 Donghua Garden, Nanshan Street, Nanshan District, Shenzhen City, Guangdong Province, 810 Applicant before: SHENZHEN YUEYAO LIFE TECHNOLOGY Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190115 |